AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38446388 — intervention group
Group type: COMPARATOR
Intervention: HEC122505 single ascending dose (5, 20, 50, 100, 200, 300, or 400 mg)
Number of subjects: 0
Study 38446388 — intervention group
Group type: COMPARATOR
Intervention: HEC122505 multiple ascending dose (20, 50, or 100 mg once daily)
Number of subjects: 0
Study 38446388 — intervention group
Group type: COMPARATOR
Intervention: HEC122505 food effect (100 mg single dose after a high-fat, high-calorie meal)
Number of subjects: 0
Study 38446388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38446397 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 828
Study 38446397 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 150 mg
Number of subjects: 828
Study 38446397 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 300 mg
Number of subjects: 828
Study 38446408 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive medical and social care (Intervention Group)
Number of subjects: 255
Study 38446408 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 255
Study 38446419 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH1 R132 mutation positive patients
Number of subjects: 0
Study 38446419 — intervention group
Group type: COMPARATOR
Intervention: Control group (IDH1 R132 mutation negative patients)
Number of subjects: 0
Study 38446471 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2-mA anodal) plus VR
Number of subjects: 54
Study 38446471 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS plus VR
Number of subjects: 54
Study 38446481 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid syndromic PCR testing (BioFire FilmArray Pneumonia plus Panel) and standard of care
Number of subjects: 374
Study 38446481 — intervention group
Group type: COMPARATOR
Intervention: Standard microbiological diagnostics alone
Number of subjects: 374
Study 38446481 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid syndromic PCR testing
Number of subjects: 374
Study 38446482 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment (coronary angiography and revascularization if feasible, n=84)
Number of subjects: 167
Study 38446482 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (medical treatment with coronary angiography only if recurrent ischemia, n=83)
Number of subjects: 167
Study 38446539 — intervention group
Group type: EXPERIMENTAL
Intervention: ChatGPT-generated outputs
Number of subjects: 11
Study 38446539 — intervention group
Group type: COMPARATOR
Intervention: Human-generated outputs
Number of subjects: 11
Study 38446568 — intervention group
Group type: EXPERIMENTAL
Intervention: Germ line NBN variant carriers (heterozygous genotypes)
Number of subjects: 4325
Study 38446568 — intervention group
Group type: COMPARATOR
Intervention: B-ALL patients with germ line NBN variants
Number of subjects: 4325
Study 38446568 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional assays for NBN variants
Number of subjects: 4325
Study 38446574 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy (GT)
Number of subjects: 0
Study 38446676 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of microplastics and nanoplastics (MNPs) in carotid artery plaque
Number of subjects: 304
Study 38446676 — intervention group
Group type: COMPARATOR
Intervention: No detection of microplastics and nanoplastics (MNPs) in carotid artery plaque
Number of subjects: 304
Study 38446675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin and pembrolizumab
Number of subjects: 886
Study 38446675 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (gemcitabine and cisplatin or carboplatin)
Number of subjects: 886
Study 38446754 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative frailty (mFI ≥ 0.21)
Number of subjects: 536
Study 38446754 — intervention group
Group type: COMPARATOR
Intervention: Nonfrailty group (mFI < 0.21)
Number of subjects: 536
Study 38446754 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative frailty (mFI)
Number of subjects: 536
Study 38446792 — intervention group
Group type: EXPERIMENTAL
Intervention: Daraja intervention (n=250)
Number of subjects: 500
Study 38446792 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care (n=250)
Number of subjects: 500
Study 38446828 — intervention group
Group type: EXPERIMENTAL
Intervention: Misdiagnosed patients with COPD
Number of subjects: 206
Study 38446828 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigated patients
Number of subjects: 206
Study 38446828 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis from healthcare professionals and misdiagnosed patients
Number of subjects: 206
Study 38446828 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from respiratory specialists
Number of subjects: 206
Study 38446867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolved oxygen during VV ECMO support
Number of subjects: 0
Study 38446860 — intervention group
Group type: EXPERIMENTAL
Intervention: In Vivo treatment
Number of subjects: 83
Study 38446860 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 83
Study 38446982 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib and binimetinib
Number of subjects: 5
Study 38447065 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise
Number of subjects: 30
Study 38447094 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 1
Study 38447095 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% nicotine e-cigarettes (EC) for 8 weeks
Number of subjects: 45
Study 38447095 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg oral nicotine pouches (ONP) for 8 weeks
Number of subjects: 45
Study 38447095 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control (CC)
Number of subjects: 45
Study 38447107 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration and lumbar puncture under sedation or general anesthesia
Number of subjects: 893
Study 38447116 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen-reduced platelet components (PRPCs)
Number of subjects: 2291
Study 38447116 — intervention group
Group type: COMPARATOR
Intervention: Conventional platelet components (CPCs)
Number of subjects: 2291
Study 38447497 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Therapy (AT)
Number of subjects: 40
Study 38447497 — intervention group
Group type: COMPARATOR
Intervention: Land-Based Therapy (LBT)
Number of subjects: 40
Study 38447622 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Listening (ML)
Number of subjects: 71
Study 38447622 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 71
Study 38447697 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase (8mg every 2 weeks) + Methotrexate (15mg/week orally)
Number of subjects: 8
Study 38447697 — intervention group
Group type: COMPARATOR
Intervention: Pegloticase (8mg every 2 weeks) + Placebo (PBO)
Number of subjects: 8
Study 38447814 — intervention group
Group type: EXPERIMENTAL
Intervention: Efruxifermin 50 mg
Number of subjects: 31
Study 38447814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 38448059 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic VA-ECMO initiation before the first pulmonary artery cross-clamp
Number of subjects: 0
Study 38448059 — intervention group
Group type: COMPARATOR
Intervention: On-demand VA-ECMO initiation based on haemodynamic and respiratory needs
Number of subjects: 0
Study 38448059 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic VA-ECMO initiation
Number of subjects: 0
Study 38448059 — intervention group
Group type: COMPARATOR
Intervention: On-demand VA-ECMO initiation
Number of subjects: 0
Study 38448064 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment with telemonitoring, home visits by a CPAP technician or nurse at CPAP initiation, followed up for 6 months.
Number of subjects: 250
Study 38448065 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised physical exercise training
Number of subjects: 115
Study 38448070 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening using capillary blood sampling
Number of subjects: 1500
Study 38448081 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic LAA clipping
Number of subjects: 290
Study 38448081 — intervention group
Group type: COMPARATOR
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 290
Study 38448281 — intervention group
Group type: EXPERIMENTAL
Intervention: elexacaftor/tezacaftor/ivacaftor (ETI)
Number of subjects: 34
Study 38448281 — intervention group
Group type: COMPARATOR
Intervention: Baseline relative abundances of potential pathogens
Number of subjects: 34
Study 38448403 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaspargase 2500 IU/m
Number of subjects: 22
Study 38448625 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stents (LAMS)
Number of subjects: 64
Study 38448625 — intervention group
Group type: COMPARATOR
Intervention: Double-pigtail plastic stents (DPS)
Number of subjects: 64
Study 38448804 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (frailty screening, shared decision-making, physiotherapy, nutrition counselling, etc.) for 3 weeks prior to surgery
Number of subjects: 0
Study 38448804 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative care (Control)
Number of subjects: 0
Study 38448874 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Internet-delivered intervention
Number of subjects: 42
Study 38448895 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy (GCBT)
Number of subjects: 33
Study 38448895 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 33
Study 38448918 — intervention group
Group type: EXPERIMENTAL
Intervention: UNIMMAP-MMS
Number of subjects: 375
Study 38448918 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folic acid (IFA)
Number of subjects: 375
Study 38448918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 38448965 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal crosslinking (CXL) treatment before transplantation, with possible repeat if insufficient reduction of corneal neovascularization is observed.
Number of subjects: 0
Study 38448965 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal crosslinking (CXL) treatment with additional fine needle diathermy on the day of transplantation.
Number of subjects: 0
Study 38448965 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (control group).
Number of subjects: 0
Study 38449031 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Interaction Profile training
Number of subjects: 200
Study 38449031 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 200
Study 38449345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative health status measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)-12
Number of subjects: 2328
Study 38449377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg IV infusion on day 1 of a 42-day cycle plus SBRT delivered in 1-5 fractions starting on C1D15-28.
Number of subjects: 0
Study 38449377 — intervention group
Group type: COMPARATOR
Intervention: SBRT in addition to current therapy for patients who have started an immune checkpoint inhibitor within 60 days.
Number of subjects: 0
Study 38449767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transplant phase
Number of subjects: 60
Study 38449767 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-weeks post-transplant
Number of subjects: 60
Study 38449767 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-months post-transplant
Number of subjects: 60
Study 38449767 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic adherence
Number of subjects: 60
Study 38449767 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood levels of prescribed drugs
Number of subjects: 60
Study 38449916 — intervention group
Group type: COMPARATOR
Intervention: Anti-PD-1 monoclonal antibody infusions
Number of subjects: 5
Study 38449910 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session housing skills training intervention
Number of subjects: 6
Study 38449910 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and technical assistance for providers
Number of subjects: 6
Study 38449910 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based format of the intervention
Number of subjects: 6
Study 38449910 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptations to the intervention (e.g., drop-in, open group format)
Number of subjects: 6
Study 38450075 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a-tDCS) combined with 4-week visuomotor stepping training (VST)
Number of subjects: 10
Study 38450075 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week visuomotor stepping training (VST)
Number of subjects: 10
Study 38450099 — intervention group
Group type: EXPERIMENTAL
Intervention: LADSS Group 1 (positive slope)
Number of subjects: 66
Study 38450099 — intervention group
Group type: EXPERIMENTAL
Intervention: LADSS Group 2 (flat slope)
Number of subjects: 66
Study 38450099 — intervention group
Group type: EXPERIMENTAL
Intervention: LADSS Group 3 (negative slope)
Number of subjects: 66
Study 38450099 — intervention group
Group type: EXPERIMENTAL
Intervention: LADSS
Number of subjects: 66
Study 38450148 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth sport (YS) participation
Number of subjects: 97
Study 38450148 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) outcomes
Number of subjects: 97
Study 38450236 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day elemental Zn
Number of subjects: 0
Study 38450236 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day elemental Zn
Number of subjects: 0
Study 38450236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38450375 — intervention group
Group type: EXPERIMENTAL
Intervention: LDE-paclitaxel (IV infusion, paclitaxel dose: 175 mg/m2)
Number of subjects: 40
Study 38450375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 38450375 — intervention group
Group type: EXPERIMENTAL
Intervention: LDE-paclitaxel
Number of subjects: 40
Study 38450496 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) with SAPIEN 3
Number of subjects: 0
Study 38450496 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study 38450513 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat therapy
Number of subjects: 15
Study 38450551 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg tablet orally 3 hours before surgery
Number of subjects: 80
Study 38450551 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet 3 hours before surgery
Number of subjects: 80
Study 38451170 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief video intervention
Number of subjects: 0
Study 38451170 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38451273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiragolumab 600 mg plus Atezolizumab 1200 mg intravenous every 3 weeks
Number of subjects: 20
Study 38451303 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management involving revision arthroplasty by experienced surgeons
Number of subjects: 1387
Study 38451303 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical approach
Number of subjects: 1387
Study 38451303 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall management of PPF
Number of subjects: 1387
Study 38451303 — intervention group
Group type: EXPERIMENTAL
Intervention: Management involving surgical delay of over 100 hours and lack of geriatric co-management
Number of subjects: 1387
Study 38451303 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-management
Number of subjects: 1387
Study 38451303 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 1387
Study 38451303 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis revision
Number of subjects: 1387
Study 38451303 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge instructions
Number of subjects: 1387
Study 38451303 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of in-hospital outcomes
Number of subjects: 1387
Study 38451426 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 1192
Study 38451491 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) to a dose of 50 Gy in 5 fractions every other day.
Number of subjects: 39
Study 38451509 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-free cyclosporine ophthalmic solution, 0.1% (1 eye drop in each eye twice daily)
Number of subjects: 206
Study 38451509 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (1 eye drop in each eye twice daily)
Number of subjects: 206
Study 38451509 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-free cyclosporine ophthalmic solution, 0.1%
Number of subjects: 206
Study 38451509 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 206
Study 38451525 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy after 3 months of DAPT
Number of subjects: 1387
Study 38451525 — intervention group
Group type: COMPARATOR
Intervention: DAPT for 12 months
Number of subjects: 1387
Study 38451604 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (initial dose 50 mg orally twice a day, increasing to a maximum of 400 mg/day for 7 days)
Number of subjects: 6
Study 38451604 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide + Opioid therapy
Number of subjects: 6
Study 38451604 — intervention group
Group type: COMPARATOR
Intervention: Opioid therapy
Number of subjects: 6
Study 38451782 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative global mean diffusivity (MD)
Number of subjects: 325
Study 38451782 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative global mean kurtosis (MK)
Number of subjects: 325
Study 38451782 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative global fractional anisotropy (FA)
Number of subjects: 325
Study 38451782 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative mean diffusivity (MD) after 3 months
Number of subjects: 325
Study 38451782 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative mean diffusivity (MD) after 12 months
Number of subjects: 325
Study 38452035 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg orally twice daily
Number of subjects: 7
Study 38452059 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg daily with Sildenafil 100 mg daily
Number of subjects: 29
Study 38452111 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated PrEP and ART delivery
Number of subjects: 83
Study 38452111 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation by HIV-negative partners
Number of subjects: 83
Study 38452111 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to implementation
Number of subjects: 83
Study 38452133 — intervention group
Group type: EXPERIMENTAL
Intervention: PUSH (16 weeks of strength, endurance, balance, and function exercises)
Number of subjects: 37
Study 38452133 — intervention group
Group type: COMPARATOR
Intervention: PULSE (seated active range-of-motion exercises and transcutaneous electrical neurostimulation)
Number of subjects: 37
Study 38452133 — intervention group
Group type: EXPERIMENTAL
Intervention: PUSH
Number of subjects: 37
Study 38452133 — intervention group
Group type: COMPARATOR
Intervention: PULSE
Number of subjects: 37
Study 38452136 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based self-efficacy intervention
Number of subjects: 158
Study 38452136 — intervention group
Group type: COMPARATOR
Intervention: waiting list control group
Number of subjects: 158
Study 38452197 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran prophylaxis (once-monthly 80 mg for 7 months)
Number of subjects: 80
Study 38452197 — intervention group
Group type: COMPARATOR
Intervention: BPA/CFC prophylaxis (for 6 months prior to switching)
Number of subjects: 80
Study 38452197 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran prophylaxis
Number of subjects: 80
Study 38452197 — intervention group
Group type: COMPARATOR
Intervention: BPA/CFC prophylaxis
Number of subjects: 80
Study 38452207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib with cytarabine (Ara-C) during consolidation (arm A)
Number of subjects: 156
Study 38452207 — intervention group
Group type: COMPARATOR
Intervention: Nilotinib without cytarabine (Ara-C) during consolidation (arm B)
Number of subjects: 156
Study 38452238 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiology-guided complete revascularization
Number of subjects: 1445
Study 38452238 — intervention group
Group type: COMPARATOR
Intervention: Culprit-only strategy
Number of subjects: 1445
Study 38452283 — intervention group
Group type: EXPERIMENTAL
Intervention: β3-AR agonist mirabegron (300 mg/day) for 6 months
Number of subjects: 70
Study 38452283 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 70
Study 38452310 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-driven genetic education webtool
Number of subjects: 315
Study 38452310 — intervention group
Group type: COMPARATOR
Intervention: Genetic counseling (GC)
Number of subjects: 315
Study 38452313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 38452313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38452327 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide with talazoparib
Number of subjects: 1035
Study 38452327 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide with placebo
Number of subjects: 1035
Study 38452496 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard bilateral rTMS
Number of subjects: 164
Study 38452496 — intervention group
Group type: COMPARATOR
Intervention: Bilateral theta burst stimulation (TBS)
Number of subjects: 164
Study 38452779 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 300 mg (single dose)
Number of subjects: 5554
Study 38452779 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day primaquine 0.5 mg/kg per day
Number of subjects: 5554